News

Two therapies used to treat hemophilia A, including the first ever recombinant therapy for hemophilia, will eventually be discontinued. Manufacturer Takeda recently…

CSL Behring has notified the hemophilia B community of a temporary global stockout of Hemgenix. This situation is not related to the…

As hemophilia treatments continue to roll out that are different than traditional factor replacement, they can offer more promising treatment but can…

Acquired hemophilia usually affects people in their 70s and 80s without warning. Here’s what you need to know. National Bleeding Disorders Foundation,…

Anti-TFPI treatments can help people with hemophilia A or B — with or without inhibitors — to better control bleeding. Source: National…

Advances include improved access to prophylaxis, multiple subcutaneous drugs in development, and research looking at better ways to personalize treatment. Source: National…

Dear Hemophilia B Community, We are writing to share an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb). CSL is currently experiencing…

Good news for the bleeding disorders community in the House of Representative’s FY26 Labor, Health and Human Services appropriations bill, which included…

The current coverage environment can create challenges for individuals seeking to explore gene therapy as a potential treatment option, as well as…

Great Lakes Hemophilia Foundation (GLHF) grieves the recent loss of Dr. Lynn Malec, a beloved Wisconsin Hematologist. Her life and work profoundly…

Certain common “natural” remedies can interfere with your body’s ability to clot. Source: National Bleeding Disorders Foundation, HemAware, February 2026

(Editors note: January 22, 2026. Following publication of this joint statement from the National Bleeding Disorders Foundation (NBDF) and the World Federation…

Good news: the House has reintroduced the HELP Copays Act, aimed at ending copay accumulator adjustor programs and copay maximizers. Learn how…

The National Bleeding Disorders Foundation (NBDF) has joined with World Federation of Hemophilia (WFH) with issuing a joint statement on a severe…

NBDF is proud to announce the 2025 recipients of the Judith Graham Pool Postdoctoral Research Fellowship, the NEHA Postdoctoral Research Fellowship, the…

Results from a phase 2 clinical trial of an investigational therapy for the treatment for Glanzmann thrombasthenia were announced by Hemab Therapeutics….

A look inside the legislation to reopen the government after the fall shutdown, a new Medicaid drug pricing model, and changes at…

Star Therapuetics has shared an update on its ongoing clinical trial of VGA039, an investigational therapy for von Willebrand disease. The therapy…

The bill aims to require insurers and pharmacy benefits managers to count all payments, including copay assistance, towards patients’ annual deductibles. Learn…

CSL Behring has published five years of data from their clinical trial of Hemgenix®, a gene therapy product for the treatment of…

This video showcases the Bleeding Disorders Research Collaborative (BDRC), a groundbreaking initiative led by the National Bleeding Disorders Foundation to transform research…

The National Bleeding Disorders Foundation (NBDF) is launching Educate to Elevate, a multi-year initiative to raise public awareness, educate communities, and improve healthcare…

At the 2025 Chapter Leadership Summit (CLS), the National Bleeding Disorders Foundation (NBDF) celebrated the generosity of chapter contributions to research.  For…

The three new recommendations concern off-label use for emicizumab for acquired hemophilia A; the use of anti-tissue factor pathway Inhibitors in hemophilia;…